Strategic realignment Adelphi Values and Mapi Group have realigned their health outcomes joint venture to provide clearer service lines and strategic opportunities, signaling potential for targeted cross-selling between PRO, psychometrics, statistics, real-world evidence, market access, and pricing capabilities.

Global collaboration With US UK alignment across Global PRO, Psychometrics, Statistics and Value Insight teams under Adelphi Values, there is a clear opportunity to pitch integrated global solutions and multi-region projects to pharmaceutical clients seeking consistent delivery across markets.

Evidence and economics Clinical and economic evidence services remain within the Mapi Group while PRO and statistics capabilities are highlighted in the new structure, suggesting sales opportunities in health economic modeling, economic value dossiers, and payer-focused market access projects.

Mid-market focus Company size indicates mid-market pharma clients as primary target, offering scalable, cost-effective analytics, compliance, and late-phase study support to mid-sized developers looking for reliable partner capabilities.

Digital and data readiness Existing tech stack including GDPR compliance, SQL, WordPress and data/analytic tools implies readiness for data-driven proposals, dashboards, and client reporting solutions to enhance value demonstrations and ongoing account management.